Enalapril: Difference between revisions

← Older edit Newer edit →

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

David Canner, Alexander Berchansky

@@ Line 7: / Line 7: @@
 * 1996 Peak Sales: $2.5 Billion
 * Importance: One of the best selling [[Angiotensin-Converting Enzyme]] Inhibitors of all time. Was developed by Merck as a replacement for [[Captopril]] with a better side effect profile.
-* The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information
+* See [[Pharmaceutical Drugs]] for more information about other drugs and diseases.
 ===Mechanism of Action===
@@ Line 15: / Line 15: @@
 {| class="wikitable" border="1" width="50%" style="text-align:center"
 |-
-!  colspan="8" align="center"| ACE-Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]] Comparison at Equivalent Dosages <ref>PMID: 7867683</ref><ref>DOI: 10.1111/j.1365-2710.2005.00646.x</ref><ref>PMID: 16075412</ref><ref>PMID:7527101</ref>
+!  colspan="8" align="center"| ACE-Inhibitor [[Pharmacokinetics]] Comparison at Equivalent Dosages <ref>PMID: 7867683</ref><ref>DOI: 10.1111/j.1365-2710.2005.00646.x</ref><ref>PMID: 16075412</ref><ref>PMID:7527101</ref>
 |-
 ! Parameter
@@ Line 26: / Line 26: @@
 ! [[Trandolapril]]
 |-
-! [[Pharmaceutical_Drugs#Tmax|T<sub>max</sub>]] (hr)
+! [[Pharmacokinetics#Tmax|T<sub>max</sub>]] (hr)
 ! .98
 ! 6.5
@@ Line 35: / Line 35: @@
 ! .72
 |-
-! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml)
+! [[Pharmacokinetics#Cmax|C<sub>max</sub>]] (ng/ml)
 ! 1210
 ! 79
@@ Line 44: / Line 44: @@
 ! 1.68
 |-
-! [[Pharmaceutical_Drugs#Bioavailability_.28F.29|Bioavailability]] (%)
+! [[Pharmacokinetics#Bioavailability_.28F.29|Bioavailability]] (%)
 ! 72
 ! 25
@@ Line 53: / Line 53: @@
 ! 10
 |-
-! [[Pharmaceutical_Drugs#Protein_Binding|Protein Binding]] (%)
+! [[Pharmacokinetics#Protein_Binding|Protein Binding]] (%)
 ! 97
 ! 0
@@ Line 62: / Line 62: @@
 ! 80
 |-
-! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr)
+! [[Pharmacokinetics#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr)
 ! .56
 ! 10.1
@@ Line 71: / Line 71: @@
 ! .68
 |-
-! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)
+! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)
 ! 1673
 ! 1016
@@ Line 80: / Line 80: @@
 ! 1.86
 |-
-! [[Pharmaceutical_Drugs#Inhibitory_Concentration_.28IC50.29|IC<sub>50</sub>]] (nM)
+! [[Pharmacokinetics#Inhibitory_Concentration_.28IC50.29|IC<sub>50</sub>]] (nM)
 ! 1.1
 ! 5.5